Switching between GLP-1 Receptor Agonists: A Clinical Practice Expert's Guide
Switching between GLP

Background Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP -1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) outcomes, mean there may be benefits to switching from one to another. However, clinical guidance on switching is lacking and data from clinical ...

This article provides a clinical perspective and consensus on the benefits of switching between GLP -1RAs, the triggers for switching and how best to manage this in clinical practice .
Switching between GLP1 receptor agonists in clinical practice

Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP‐1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) outcomes, mean there may be benefits to switching from one to another. However, clinical guidance on switching is lacking and ...
This article provides a clinical perspective and consensus on the benefits of switching between GLP -1RAs, the triggers for switching and how best to manage this in clinical practice .

Switching between GLP
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP‐1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) outcomes, mean there may be benefits to switching from one to another. However, clinical guidance on switching is lacking and data from ...
This article provides a clinical perspective and consensus on the benefits of switching between GLP -1RAs, the triggers for switching and how best to manage this in clinical practice . Once weekly (OW) semaglutide is used as an example to illustrate how the authors might switch to a different GLP -1RA in clinical practice .

Switching between GLP1 receptor agonists in clinical practice
Abstract was not provided for this article. Switching between GLP‐1 receptor agonists in clinical practice Expert consensus and practical guidance
Switching between GLP‐1 receptor agonists in clinical practice : Expert consensus and practical guidance Akshay B. Jain, Amar Ali, Juan J. Gorgojo Martínez, Irene Hramiak, Ketan Kavia, Sten Madsbad, Louis Potier, Ben D. Prohaska, Jodi L. Strong, Tina Vilsbøll Department of Clinical Medicine Internal Medicine: Endocrinology

Switching between GLP1 receptor agonists in clinical practice
However, clinical guidance on switching is lacking and data from clinical trials are limited. This article provides a clinical perspective and consensus on the benefits of switching between GLP‐1RAs, the triggers for switching and how best to manage this in clinical practice .




This review focuses on injectable GLP -1RAs and provides a clinical perspective and consensus on the benefits of switching between GLP -1RAs, the triggers for initiating switching and how best to manage this in clinical practice . ...